Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation.
Christopher J GibsonHaesook T KimLin ZhaoH Moses MurdockBryan C HambleyAlana F OgataRafael Madero-MarroquinShiyu WangLisa GreenMark FlehartyTyler J DouganChi-An ChengBrendan BlumenstielCarrie CibulskisJunko TsujiMadeleine DuranChristopher D GockeJoseph H AntinSarah NikiforowAmy E DeZernYi-Bin ChenVincent T HoRichard J JonesNiall J LennonDavid R WaltJerome RitzRobert J SoifferLukasz P GondekR Coleman LindsleyPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Donor CH is closely associated with clinical outcomes in transplant recipients, with differential impact on graft alloimmune function and potential for leukemic transformation related to mutated gene and somatic clonal abundance. Donor DNMT3A-CH is associated with improved recipient survival because of reduced relapse risk and with an augmented network of inflammatory cytokines in recipients. Risk of DCL in allogeneic hematopoietic cell transplantation is driven by somatic myelodysplastic syndrome-associated mutations or germline predisposition in donors.